Methyldopa tablet overdosage: Difference between revisions

Jump to navigation Jump to search
(Redirected page to Methyldopa#Overdosage)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Methyldopa#Overdosage]]
{{Methyldopa}}
{{CMG}}; {{AE}} {{AK}}
 
==Overdosage==
 
Acute overdosage may produce acute [[hypotension ]]with other responses attributable to brain and gastrointestinal malfunction (excessive [[sedation]], weakness, [[bradycardia]], [[dizziness]], light-headedness, [[constipation]], [[distention]], [[flatus]], [[diarrhea]], [[nausea]], [[vomiting]]).
 
In the event of overdosage, symptomatic and supportive measures should be employed. When ingestion is recent, gastric lavage or [[emesis ]]may reduce absorption. When ingestion has been earlier, infusions may be helpful to promote urinary excretion. Otherwise, management includes special attention to cardiac rate and output, blood volume, electrolyte balance, [[paralytic ileus]], urinary function and cerebral activity.
 
Sympathomimetic drugs [e.g., [[levarterenol]], [[epinephrine]], ARAMINE®1 ([[Metaraminol ]]Bitartrate)] may be indicated. Methyldopa is [[dialyzable]].
 
The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat.
 
<sup>1</sup>
 
ARAMINE® is a registered trademark of Merck.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = METHYLDOPA TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87d63fd-48f7-4130-af03-5e263c338fe4 | publisher =  | date =  | accessdate = 10 March 2014 }}</ref>
 
==References==
 
{{Reflist|2}}
 
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Latest revision as of 00:15, 22 July 2014